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idiopathic short stature (ISS) during growth hormone (GH) treatment. The aim of this study
was to evaluate the effect of GH treatment on craniofacial growth in children with ISS,
compared with those with growth hormone deficiency (GHD).
Methods: This study included 36 children (mean age, 11.3  1.8 years) who were treated with
GH consecutively. Lateral cephalograms were analyzed before and 2 years after start of GH
treatment.
Results: There were no significant differences in age and sex between ISS and GHD groups and
the reference group from semilongitudinal study (10 boys and 8 girls from each group). Before
treatment, girls with ISS showed a skeletal Class II facial profile compared with the GHD and
reference groups (pZ 0.003). During GH treatment, the amount of maxillary length increased
beyond norm in the ISS and GHD groups in boys (pZ 0.035) > 3 standard deviation score (SDS).
Meanwhile, mandibular ramus height (p Z 0.001), corpus length, and total mandibular length
(p Z 0.007 for both) increased more in girls with ISS than in girls with GHD. Lower and total
anterior facial heights increased more in girls with ISS than in girls with GHD (p Z 0.021 and
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Growth disorders, associated with growth hormone (GH) in
children, include growth hormone deficiency (GHD), idio-
pathic short stature (ISS), Noonan syndrome, PradereWilli
syndrome, and Turner syndrome.1,2 Among these, ISS is
defined as a height less than third percentile or two SDs
(standard deviations) for age, sex, and population without
evidence of nutritional, systemic chronic disease, endo-
crine, and chromosomal abnormalities.3,4 The cause of ISS
may be gene mutations and deletions in the SHOX gene for
children, the prevalence has been estimated at 1e5%.4,5 In
addition, a karyotype should be considered in girls with no
underlying specific cause of ISS to rule out Turner syndrome.4
As childrenwith ISS often remain short inadult life, in2003,
the United States (US) Food and Drug Administration (FDA)
approved use of GH for treatment of ISS in children whose
presenting height is<2.25 SDs for age, sex, and that height
in adult life is expected to be below normal.6 Several studies
concluded thatGH therapy can result inhigher adult heights in
some treated children.7e9 The consensus was that the mean
increase in adult height with GH therapy is 3.5e7.5 cm.10
However, to the best of our knowledge, few studies have
evaluated craniofacial growth in ISS during GH treatment.
Kjellberg et al11 reported an enhancement of overall
craniofacial growth in boys with ISS and the mandibular
body length and anterior facial height of the boys treated
GH were greater at the end of treatment compared with
those in the reference group. However, that study had a
limitation that girls with ISS were not included as subjects
because most children seeking GH treatment were boys.
Grimberg et al12 reported that sex difference in short
stature referrals may miss the diagnosis and treatment of
diseases in girls whose growth problems are undervalued.
Therefore, growth change of the craniofacial complex in
girls with ISS should be determined during GH treatment.
The aim of this study was to evaluate the effect of GH
treatment on craniofacial growth in children with ISS,
compared with those with GHD. The investigators hypoth-
esize that craniofacial growth pattern is significantly
different between children, especially girls with ISS and
those with GHD 2 years after GH treatment.
Methods
Study design/sample
The study population comprised 40 children who presented
for evaluation and management of short statue with ISS or
with GHD who underwent GH treatment from 2006 to 2012
at the Department of Pediatrics, Yeungnam University
Hospital, Daegu, Korea.
Inclusion criteria were as follows: chronological age
> 5 years old; less than third percentile or two SDs belowthe normal mean height for subjects of a similar age and
sex or growth velocity according to the Korean popula-
tion;13 no history of GH treatment within 6 months; pre-
pubertal stage according to Tanner stage criteria based on
testicular volume in boys and breast development in girls.
Among a total of 40 children whose caregivers agreed with
taking radiographs for measurements of the cephalometics,
four dropped out (two from each group) 1 year after GH
treatment because two refused to continue the treatment and
two were lost to follow-up, 18 patients were diagnosed with
idiopathic GHD and 18 patients were diagnosed with ISS. The
clinical diagnosis of GHD was defined by height less than the
third percentile and peak GH response< 10 ng/mL after one of
three growth hormone stimulation tests using insulin, L-dopa,
and clonidine. ISS was defined when patients had short stature
less than third percentile without evidence of a systemic dis-
ease, nutritional, psychological of chromosomal disorder, and
peak GH response more than 10 ng/mL after growth hormone
stimulation tests. The patients were injected with 0.23 mg of
recombinant growth hormone (rGH) /kg/week (mean dose), six
times weekly for 2 years. The study protocol conforms to the
Declaration of Helsinki and was approved by the Institutional
Review Board of Yeungnam University Hospital, Daegu, Korea.
Reference group
The reference group consisted of healthy children with Class I
molar relationships and normal occlusion selected from
elementary schools in Daegu. Semilongitudinal growth study
data traced and surveyed for 10 years from May 1983 by the
Department of Orthodontics, Kyungpook National University
Hospital, Daegu, Korea, were used. Eighteen children data
were selected to fit those of the short-statured children.
Cephalometric analysis
Patients and their parents were asked if they would agree
to allow measurement of their craniofacial structure by an
orthodontist at the Department of Dentistry, Yeungnam
University Hospital, Daegu, Korea, before undergoing GH
treatment. For those who agreed, a written informed
consent was obtained from each patient and parents before
GH treatment. Craniofacial growth changes were evaluated
using lateral cephalograms obtained before (T0) and 2 years
(T1) after start of GH treatment. The lateral cephalograms
were digitized using V-ceph 5.5 (Osstem, Seoul, Korea) by
an observer who was blinded to the patients’ clinical sta-
tus. Based on the Pancherz’s cephalometric method,14 all
reference planes were transferred from the T0 to T1
cephalograms according to the S (sella)-N (nasion) plane
superimposition at S. This study identified nine linear and
seven angular cephalometric measurements to evaluate the
change of the craniofacial complex in each group during GH
treatment (Figure 1).
Figure 1 Cephalometric reference points, lengths, and an-
gles. A Z point A; ANB, maxilla-mandible relation;
ANS Z anterior nasal spine; ANS-Me Z lower anterior facial
height; ANS-PNS Z maxillary length; Ar Z articulare; Ar-
Gn Z total mandibular length; Ar-Go Z mandibular ramus
height; Ar-Go-Me Z gonial angle; B Z point B; Ba Z basion;
Gn Z gnathion; Go Z gonion; Go-Gn Z mandibular corpus
length; Me Z menton; N Z nasion; N-Me Z total anterior
facial height; N-S Z anterior cranial base length; N-S-
Ar Z cranial base angle; PNS Z posterior nasal spine;
S Z sella; S-Ba Z posterior cranial base length; S-
Go Z posterior facial height; SNA Z maxilla-cranial base
relation; SN-ArGoZ ramal angle; SNBZmandible-cranial base
relation; SN-GoMe Z mandibular plane angle.
Table 1 Subjects characteristics.
GHD g
(n Z
Sex n (%)
Boys 10 (55
Girls 8 (44.
Chronological age (mean  SD, year) 11.3 
(Range) (9e15
Body height (median, cm)
Boys Before GH treatment 128.7
At 2 years after start of GH treatment 148.8
Girls Before GH treatment 124.4
At 2 years after start of GH treatment 143.6
Body weight (median, kg)
Boys Before GH treatment 29.4
At 2 years after start of GH treatment 42.1
Girls Before GH treatment 24.1
At 2 years after start of GH treatment 36.6
GHDZ growth hormone-deficient; GHZ growth hormone; ISSZ idiop
deviation.
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Reproducibility was determined by comparing measure-
ments obtained during original examinations with those
obtained during repeated examinations. All measure-
ments were repeated by the same observer after
2 weeks. The method error was calculated using the
intraclass correlation coefficient (ICC), which was > 0.90
for all linear and angular cephalometric measurements
used in this study.
Statistical analysis
All statistical analyses were performed using IBM SPSS
software, version 21.0 (IBM Korea Inc., Seoul, Korea) for
Windows. In order to verify the normality of data distribu-
tion, the ShapiroeWilk test was applied. Descriptive sta-
tistics, including means and standard deviations, were used
to describe each variable analyzed in the study. Differences
in patients’ heights and weights between groups were
analyzed using the KruskaleWallis test.
The KruskaleWallis test with Bonferroni correction
was used for comparison of cephalometric measurements
in each boy or girl between groups before (T0) and
2 years after start of GH treatment (T1). All variables
were converted standard deviation score (SDS) using the
reference group for comparison of craniofacial growth
changes (T1eT0) during GH treatment between groups,
using the ManneWhitney U test. SDS was calculated as
measurement minus mean of the reference group divided
by standard deviation of the reference group. Thus, a
positive standard score indicates a datum above the
mean, while a negative standard score indicates a datum
below the mean.
Correlations between craniofacial growth changes, age,
sex, and groups (the GHD and the ISS) were evaluated using
Spearman’s rank correlation coefficients. With regard to
the strengths of the correlations, r > 0.40 indicated a
moderate-to-strong correlation and r < 0.40 indicated aroup
18)
ISS group
(n Z 18)
Reference group
(n Z 18)
P value
NS
.6) 10 (55.6) 10 (55.6)
4) 8 (44.4) 8 (44.4)
1.9 11.2  1.8 10.8  1.8 NS
) (9e15) (9e15)
132.4 139.4 < 0.001
150.5 151.8 NS
125.7 139.9 < 0.001
150.8 152.7 NS
33.2 35.5 < 0.001
52 45.5 NS
25.0 34.7 < 0.001
40.6 43.8 NS
athic short stature; NS, not statistically significant; SDZ standard
Table 2 Mean and standard deviation of cephalometric measurements between groups before growth hormone treatment.
Variables Boys Post
hoc
Girls Post hoc
GHD groupa ISS groupb Reference
groupc
p GHD groupa ISS groupb Reference
groupc
P
Linear measurements (mm)
Anterior cranial base length (N-S) 64.23  1.98 65.90  3.06 68.60  1.35 0.002 a< c 63.75  1.36 65.81  1.51 68.19  1.79 0.001 a< c
Posterior cranial base length (S-Ba) 44.17  2.61 46.20  2.53 49.20  2.96 0.004 a< c 44.50  3.22 43.63  0.74 43.63  2.74 0.699
S-Ba/N-S (%) 68.73  2.51 70.16  3.47 71.67  3.04 0.091 69.75  3.97 66.30  1.10 63.93  2.42 0.007 a> c
Maxillary length (ANS-PNS) 44.10  3.29 46.60  4.27 47.00  3.62 0.103 44.75  2.36 42.94  0.62 46.38  1.58 0.004 b < c
Mandibular ramus height (Ar-Go) 38.55  3.02 39.40  2.37 43.70  4.54 0.012 a< c 36.13  4.36 36.81  4.88 42.49  2.23 0.010 a< c
Mandibular corpus length (Go-Gn) 68.50  4.63 73.65  1.63 74.60  4.14 0.008 a< b,
a< c
70.38  4.30 68.88  1.55 73.69  2.96 0.011
Ar-Go/Go-Gn (%) 56.50  5.90 53.52  3.40 58.47  3.29 0.030 51.18  3.22 53.33  5.97 57.64  1.00 0.009 a< c
Total mandibular length (Ar-Gn) 97.00  5.52 103.30  4.79 102.1  5.26 0.026 98.13  3.76 98.13  2.59 99.38  6.52 0.647
Lower anterior facial height
(ANS-Me)
65.65  3.50 67.60  3.61 65.13  3.19 0.302 63.88  2.22 62.63  0.52 63.75  4.41 0.570
Anterior facial height (N-Me) 114.85  4.70 118.50  6.94 118.71  5.35 0.159 113.44  1.32 113.00  1.51 115.06  6.06 0.901
Posterior facial height (S-Go) 67.35  5.07 68.05  7.11 74.41  6.82 0.088 68.44  4.44 66.81  2.09 70.88  2.89 0.113
Angular measurements ()
Cranial base angle (N-S-Ar) 127.90  4.23 125.95  3.75 122.10  1.85 0.004 a> c 124.13  4.35 125.81  1.81 127.19  1.81 0.079
Ramal angle (SN-ArGo) 88.25  3.62 87.20  2.26 86.2  3.44 0.123 87.56  4.69 86.38  1.55 86.88  1.55 0.284
Gonial angle (Ar-Go-Me) 127.50  3.95 125.00  1.37 124.20  2.66 0.415 127.25  3.22 126.56  0.78 127.38  8.15 0.917
Mandibular plane angle (SN-GoMe) 35.15  2.31 36.15  3.73 33.20  0.71 0.010 36.38  3.37 37.13  2.39 36.56  8.50 0.573
Maxilla-cranial base relation (SNA) 79.00  2.87 80.65  3.61 79.75  1.30 0.388 80.75  2.60 81.13  1.77 78.31  0.70 0.011
Mandible-cranial base relation (SNB) 74.70  3.68 76.95  3.26 77.30  1.72 0.178 77.50  3.74 76.00  1.69 75.25  1.46 0.500
Maxilla-mandible relation (ANB) 4.30  1.44 3.60  1.20 2.40  0.77 0.018 a> c 3.19  1.51 5.13  0.52 3.06  1.29 0.003 a< b,
b> c
P values were calculated by the Kruskal-Wallis test with Bonferroni correction.
GHD Z growth hormone-deficient; ISS Z idiopathic short stature.
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GH can result in longer face in girl with ISS 317weak correlation. A p value  0.05 or less was considered
significant.Results
Thirty six patients (20 boys and 16 girls; mean age,
11.3  1.8 years) fulfilled the inclusion criteria for this
study (Table 1). There were no significant differences in age
and sex between ISS, GHD, and the reference groups (10
boys and 8 girls from each group). Body heights and weights
of boys and girls were lower in the GHD and ISS groups
compared with the reference group before GH treatment
(p < 0.001). After GH treatment, body heights and weights
in children with GHD and those with ISS were almost the
same as those in children in the reference group, proving
the effect of 2 years of GH treatment in children with both
idiopathic GHD and ISS.
Before GH treatment, boys with GHD had shorter
anterior and posterior cranial base lengths (pZ 0.002 and
pZ 0.004, respectively) and mandibular ramus height and
corpus length (p Z 0.012 and p Z 0.008, respectively)
than those in the reference group (Table 2). In addition,
boys with GHD had greater maxilla-mandible relation
(ANB) than those with reference group (p Z 0.018),
indicating that boys with GHD had skeletal Class II ten-
dency compared with boys with the reference group
before GH treatment. Likewise, girls with GHD had shorter
anterior cranial base length (p Z 0.001) and mandibular
ramus height (p Z 0.010) than those in the reference
group (Table 2). Girls with ISS had greater ANB (pZ 0.003)Table 3 Changes of standard deviation scores (SDS) of transfo
between groups.
Variables Boys
GHD group ISS g
Linear measurements (mm)
Anterior cranial base length (N-S) 3.42  1.12 2.6
Posterior cranial base length (S-Ba) 1.51  1.44 1.4
Maxillary length (ANS-PNS) 5.47  3.21 3.1
Mandibular ramus height (Ar-Go) 1.45  0.73 1.5
Mandibular corpus length (Go-Gn) 1.45  2.25 0.6
Total mandibular length (Ar-Gn) 0.94  1.99 0.2
Lower anterior facial height (ANS-Me) 1.80  0.72 1.8
Total anterior facial height (N-Me) 2.95  1.79 0.1
Posterior facial height (S-Go) 3.57  1.71 1.2
Angular measurements ()
Cranial base angle (N-S-Ar) 1.31  3.56 1.8
Ramal angle (SN-ArGo) 0.63  1.45 1.3
Gonial angle (Ar-Go-Me) 1.46  5.53 0.4
Mandibular plane angle (SN-GoMe) 1.20  2.31 1.4
Maxilla-cranial base relation (SNA) 1.05  2.06 2.1
Mandible-cranial base relation (SNB) 0.01  0.89 0.9
Maxilla-mandible relation (ANB) 0.58  1.26 0.1
P values were calculated by the ManneWhitney U-test.
GHD Z growth hormone-deficient; ISS Z idiopathic short stature.than those in the GHD and reference groups, indicating
that girls in the ISS group had skeletal Class II facial profile
compared with the GHD and reference groups before GH
treatment.
During GH treatment, most measurements improved
toward norm in boys with GHD and those with ISS (Table 3).
Significantly accelerated growth beyond norm was observed
in the two groups for maxillary length over 3 SDS
(p Z 0.035). There were no significant differences in the
amounts of change in angular measurements between the
groups. The amounts of increase in posterior cranial base
length was greater in girls with GHD than in girls with ISS
(p Z 0.021). Mandibular ramus height (p Z 0.001), corpus
length, and total mandibular length (p Z 0.007 for both)
increased more in girls with ISS than in girls with GHD, over
3e6 SDS (Figure 2). As a result, lower and total anterior
facial heights increased significantly more in girls with ISS
than in girls with GHD (p Z 0.021 and p Z 0.007, respec-
tively), over 7e11 SDS.
Two years after GH treatment, the sagittal skeletal
relationship improved significantly in boys with GHD and
those with ISS, compared with boys in the reference group
(Table 4). Lower and total anterior facial heights were
significantly greater in girls in the ISS group than in girls in
the reference groups (pZ 0.026 and p Z 0.007, respec-
tively). Posterior facial heights were greater in girls with
ISS compared with those in the reference group
(p Z 0.007).
With younger age at the start of GH treatment, the
amounts of increase in posterior cranial base length (r,rmed outcome variables during growth hormone treatment
Girls
roup p GHD group ISS group p
7  0.98 0.063 4.44  2.51 2.12  0.30 0.050
5  1.07 0.853 4.40  2.15 1.97  1.23 0.021
4  2.10 0.035 1.55  1.37 2.17  0.51 0.328
9  0.74 1.000 1.97  0.70 4.73  2.12 0.001
5  3.00 0.529 2.24  3.26 6.59  1.13 0.007
2  2.43 0.315 0.89  2.37 3.67  0.64 0.007
0  2.13 0.436 3.02  2.71 7.51  3.86 0.021
4  5.46 0.023 1.11  2.53 11.13  7.66 0.007
9  3.13 0.029 3.76  2.45 4.90  1.06 0.382
5  4.07 0.853 0.35  1.09 0.58  0.73 0.645
1  1.34 0.218 0.06  1.94 0.70  0.22 0.328
7  3.85 0.436 0.17  2.01 0.19  1.50 0.959
8  2.03 0.796 0.82  0.99 0.21  0.18 0.234
2  9.52 0.684 0.38  0.40 0.41  0.28 0.959
5  3.98 0.684 0.27  2.23 0.82  0.77 0.382
0  1.76 0.143 0.53  0.45 0.75  0.51 0.382
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GH can result in longer face in girl with ISS 3190.451; p < 0.01), maxillary length (r, 0.541; p < 0.001),
and total mandibular length (r, 0.353; p < 0.05)
increased during GH treatment (Table 5). The amounts of
mandibular corpus length and total mandibular length
increased more in girls than in boys by GH (r, 0.442e0.446;
p < 0.01 for both). By contrast, anterior cranial base
length increased more in boys than in girls (r, 0.636;
p < 0.001). The mandibular ramus height increased more
in children with ISS than in those with GHD (r, 0.376;
p < 0.05). Anterior and posterior cranial base lengths
increased more in children with GHD than in those with ISS
during GH treatment (r, 0.349e0.334; p < 0.05 for
both).Discussion
The aim of this study was to evaluate the effect of GH on
craniofacial growth in children with ISS, compared with
those with GHD. The hypothesis was that craniofacial
growth pattern is significantly different between girls with
ISS and those with GHD. The results showed that there
were no significant intergroup differences in boys after GH
treatment (Table 4). However, the amount of the
mandibular growth was significantly greater in girls with ISS
than in those with GHD during GH treatment. As a result,
anterior facial height in girls with ISS was greater than
those in the reference group at 2 years after start of GH
treatment.
Kjellberg et al11 reported that a prognathic growth
pattern and anterior rotation of the mandible was seen
after GH treatment in GHD and ISS boys and there were no
differences in growth response between two groups. The
results of this study are somewhat consistent with their
results. In this study, the amount of maxillary length in boys
in both groups increased more than three SDS and there was
no significant difference in the amount of mandibular
length in boys between groups during GH treatment (Table
3). However, the mandibular growth increased more in girls
with ISS than in those with GHD (Figure 2). As mandibular
ramus height, corpus length, and total mandibular length of
girls with ISS increased significantly more than that in those
with GHD, lower and total anterior facial heights of girls
with ISS were overdeveloped in girls with ISS after 2 years
after GH treatment.
These results indicated that the interstitial cartilage
growth of the condyles by GH is influenced more in girls
with ISS than girls with GHD and mandibular growth by GH
was in the vertical, not sagittal, direction for girls with
ISS. Although there was no significant difference between
groups, the ANB was greater in girls with ISS than in other
groups. This mandibular vertical growth direction is that
included an increase in anterior facial height in girls withFigure 2 Changes of mandibular growth and anterior facial heig
contrast the results observed in boys, mandibular ramus height, cor
more in girls with ISS than in girls with GHD during GH treatment;
facial heights were significantly greater in girls in the ISS group than
GHD Z growth hormone deficiency; ISS Z idiopathic short stature;
treatment.ISS appears similar to patients with Turner syndrome.
Previous studies reported that total mandibular length
increased significantly, thereby increasing anterior facial
height in Turner syndrome.15,16 These catch-up growth
patterns would not cause an acromegalic facial profile
but a long facial profile, which is not what the patient
wants at the start of GH treatment. Therefore, in treat-
ment of girls with ISS and posterior mandibular growth
rotation at the start of GH supplementation, GH should
be administered carefully and long term follow-up would
be necessary.
In this study, posterior cranial base length and maxil-
lary length showed negative and moderate correlation
with age (Table 5). Previous studies also reported that the
younger the children at the start of GH treatment, the
greater the residual growth potential and greater the
craniofacial growth promoting effect.17,18 Anterior cranial
base length in boys and mandibular growth in girls could
be influenced by GH. These differences in growth area by
GH according to sex might be related to sex difference in
growth spurts time or residual growth potential.19 Addi-
tionally, increase of mandibular ramus height could be
greater in children with ISS than in children with GHD and
increase in anterior and posterior cranial base lengths
could be greater in children with GHD than in children
with ISS. The early cessation of growth in the syn-
chondroses of the cranial base along with the fact that GH
affects primary sites with endochondral ossification mean
that GH treatment should be started at an early age to
improve cranial base development in children with GHD.19
This study had several limitations to interpretation of
the data: (1) the study included a limited number of
subjects, which may limit the ability to extrapolate these
findings to the wider population; and (2) although GH
treatment could have an effect on craniofacial catch-up
growth in short-term, long-term effect should be explored
further. Future studies with adequate sample size and
long-term follow-up are necessary to evaluate final dif-
ference in craniofacial skeletal growth between adults
with ISS and those with GHD according to sex.
In summary, craniofacial growth increased toward the
norm in children with idiopathic short stature or growth
hormone deficiency during growth hormone treatment but
some parts of the face may be influenced beyond the
normal growth which can lead to an increased mandible
and a longer face. In particular, greater increase in
mandibular growth and anterior facial height were
observed in girls with idiopathic short stature than those
in the reference group during growth hormone treatment.
Therefore, because growth hormone can result in a long
facial profile, due to vertical overgrowth of the mandible,
growth hormone treatment should be used with caution
when treating girls with idiopathic short stature.ht by growth hormone (GH) in boys and girls. (A, B, and C) By
pus length, and total mandibular length significantly increased
(D and E) 2 years after GH treatment, lower and total anterior
in girls in the reference groups. ControlZ the reference group;
T0 Z before GH treatment; T1 Z at 2 years after start of GH
Table 4 Mean and standard deviation of cephalometric measurements between groups after growth hormone treatment.
Variables Boys Post
hoc
Girls Post hoc
GHD groupa ISS groupb Reference
groupc
p GHD groupa ISS groupb Reference
groupc
P
Linear measurements (mm)
Anterior cranial base length (N-S) 69.40  2.41 70.2  3.01 69.80  0.98 0.640 67.13  2.47 67.88  1.55 69.00  2.07 0.134
Posterior cranial base length (S-Ba) 48.55  2.24 50.50  2.59 51.75  2.55 0.144 49.56  1.68 46.38  0.52 44.50  2.93 0.001 a> b,
a> c
S-Ba/N-S (%) 69.98  2.97 72.05  4.60 74.12  3.19 0.146 73.87  2.18 68.37  2.35 64.43  2.29 < 0.001 a> b > c
Maxillary length (ANS-PNS) 48.85  2.82 50.00  4.01 48.58  3.57 0.789 49.50  2.12 49.13  1.55 47.56  0.78 0.088
Mandibular ramus height (Ar-Go) 44.65  3.27 45.85  1.49 46.05  5.75 0.443 42.00  3.95 46.00  4.74 46.00  2.48 0.069
Mandibular corpus length (Go-Gn) 73.30  6.41 77.65  3.24 77.95  3.76 0.180 75.63  2.13 78.13  2.59 76.88  2.71 0.088
Ar-Go/Go-Gn (%) 61.26  6.43 59.09  1.73 58.93  4.99 0.849 55.48  4.10 58.78  4.60 59.81  1.52 0.029
Total mandibular length (Ar-Gn) 103.20  3.21 108.35  5.13 106.80  4.79 0.026 104.88  2.08 109.38  3.62 104.69  4.93 0.052
Lower anterior facial height (ANS-Me) 70.40  2.87 72.35  3.51 67.31  3.76 0.147 68.31  2.05 71.06  3.36 65.50  3.73 0.026 b > c
Total anterior facial height (N-Me) 123.50  4.90 122.65  7.54 123.06  5.72 0.540 119.00  2.39 128.19  5.95 119.56  6.26 0.007 a< b,
b> c
Posterior facial height (S-Go) 78.35  5.90 75.40  2.80 79.70  7.27 0.319 78.50  1.58 78.63  0.52 75.19  3.47 0.007 b > c
Angular measurements ()
Cranial base angle (N-S-Ar) 129.40  3.10 127.90  2.22 122.50  1.43 0.260 126.31  4.64 128.25  1.04 129.00  0.93 0.201
Ramal angle (SN-ArGo) 88.15  2.88 85.65  3.18 87.45  2.72 0.042 87.88  4.35 87.56  1.29 87.25  1.46 0.731
Gonial angle (Ar-Go-Me) 125.80  3.76 125.35  4.94 124.05  3.15 0.674 126.75  3.12 126.31  1.81 127.00  8.73 0.884
Mandibular plane angle (SN-GoMe) 33.10  2.23 33.90  3.51 32.00  0.71 0.462 34.25  3.06 35.88  2.59 35.63  9.94 0.373
Maxilla-cranial base relation (SNA) 79.40  3.06 82.35  1.76 80.58  0.98 0.015 a< b 80.50  2.19 80.81  2.33 78.88  2.79 0.168
Mandible-cranial base relation (SNB) 76.20  3.26 79.30  1.64 78.81  1.18 0.032 a< b 78.13  2.79 76.88  1.55 75.75  1.67 0.106
Maxilla-mandible relation (ANB) 3.20  1.55 3.05  1.30 1.77  0.75 0.906 2.38  1.30 3.94  0.78 3.13  2.46 0.122
P values were calculated by the Kruskal-Wallis test with Bonferroni correction.
GHD Z growth hormone-deficient; ISS Z idiopathic short stature.
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Table 5 Correlation coefficient between sex, age, groups (GHD and ISS), and changes (standard deviation scores) of variables
during growth hormone treatment.
Variables Age Sex Groups
r p r p r p
Linear measurements (mm)
Anterior cranial base length (N-S) 0.219 NS 0.636 *** 0.349 *
Posterior cranial base length (S-Ba) 0.451 ** 0.157 NS 0.334 *
Maxillary length (ANS-PNS) 0.541 *** 0.274 NS 0.008 NS
Mandibular ramus height (Ar-Go) 0.243 NS 0.246 NS 0.376 *
Mandibular corpus length (Go-Gn) 0.002 NS 0.442 ** 0.269 NS
Total mandibular length (Ar-Gn) 0.353 * 0.446 ** 0.207 NS
Lower anterior facial height (ANS-Me) 0.286 NS 0.182 NS 0.184 NS
Total anterior facial height (N-Me) 0.040 NS 0.156 NS 0.019 NS
Posterior facial height (S-Go) 0.195 NS 0.198 NS 0.161 NS
Angular measurements ()
Cranial base angle (N-S-Ar) 0.679 *** 0.038 NS 0.129 NS
Ramal angle (SN-ArGo) 0.254 NS 0.406 * 0.014 NS
Gonial angle (Ar-Go-Me) 0.487 ** 0.100 NS 0.089 NS
Mandibular plane angle (SN-GoMe) 0.394 * 0.125 NS 0.092 NS
Maxilla-cranial base relation (SNA) 0.192 NS 0.337 * 0.074 NS
Mandible-cranial base relation (SNB) 0.345 * 0.312 NS 0.047 NS
Maxilla-mandible relation (ANB) 0.081 NS 0.105 NS 0.116 NS
Sex (male, 1; female, 2) and groups GHD Z growth hormone-deficient, 1; ISS Z idiopathic short stature, 2.
NS Z not significant.
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